Enliven Therapeutics (NASDAQ:ELVN) COO Sells $140,056.26 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel sold 6,663 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $21.02, for a total value of $140,056.26. Following the completion of the transaction, the chief operating officer directly owned 263,311 shares of the company’s stock, valued at approximately $5,534,797.22. This trade represents a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Anish Patel also recently made the following trade(s):

• On Friday, November 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The shares were sold at an average price of $17.40, for a total value of $116,005.80.
• On Tuesday, October 7th, Anish Patel sold 6,667 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.10, for a total transaction of $134,006.70.

Enliven Therapeutics Trading Up 3.5%

Shares of NASDAQ ELVN traded up $0.68 during midday trading on Wednesday, reaching $20.17. 1,095,001 shares of the stock were exchanged, compared to its average volume of 432,699. The stock has a 50 day moving average price of $20.86 and a 200-day moving average price of $20.43. The company has a market capitalization of $1.20 billion, a P/E ratio of -10.96 and a beta of 0.35. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $25.37.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.11. On average, analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Institutional Trading of Enliven Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Goldman Sachs Group Inc. increased its position in shares of Enliven Therapeutics by 61.3% in the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock worth $4,167,000 after acquiring an additional 80,506 shares in the last quarter. Affinity Asset Advisors LLC acquired a new position in shares of Enliven Therapeutics during the 2nd quarter valued at $8,024,000. Wellington Management Group LLP boosted its position in Enliven Therapeutics by 4.7% during the 1st quarter. Wellington Management Group LLP now owns 84,700 shares of the company’s stock worth $1,667,000 after purchasing an additional 3,784 shares during the period. Russell Investments Group Ltd. boosted its position in Enliven Therapeutics by 148,550.7% during the 1st quarter. Russell Investments Group Ltd. now owns 105,542 shares of the company’s stock worth $2,077,000 after purchasing an additional 105,471 shares during the period. Finally, Ally Bridge Group NY LLC increased its holdings in Enliven Therapeutics by 19.8% in the 1st quarter. Ally Bridge Group NY LLC now owns 169,774 shares of the company’s stock valued at $3,341,000 after purchasing an additional 28,064 shares in the last quarter. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have commented on ELVN shares. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, October 8th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $41.20.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.